Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, has announced the successful closing of an $11.6 ...

Pfizer will relinquish its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's interest and simplifies the shareholder structure of the HIV specialist. Under ...

Office of Management and Budget (OMB) Director Russell Vought. A move by the Trump administration to block new NIH research funding for external research teams, as well as some renewals, appears to ...

Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, collectively raising more than $1.2 billion – with all overshooting ...

Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now expected to be down around $9 ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to improve ...

A hacking group claims to have broken into AstraZeneca's IT systems and stolen confidential data, which they are now offering for sale. The group, known as LAPSUS$, maintain that they have stolen ...

Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partner companies. The move – described as a "sharpening" of ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – has announced that the US Food and Drug Administration (FDA) has issued a ...

Matchpoint Therapeutics is preparing to take its oral T cell modulator through proof-of-concept clinical testing in ...

Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after reporting topline results from a pivotal phase 3 trial. In the AFFINITY DUCHENNE ...

Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug ...